Biomarker-Guided cocktail aims to slow kidney failure

NCT ID NCT07239570

Recruiting now Disease control Sponsor: Peter Rossing Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using specific biomarkers to choose and combine three kidney-protecting drugs (dapagliflozin, semaglutide, and finerenone) can slow kidney function decline better than standard care. About 125 adults with chronic kidney disease and albuminuria will be randomly assigned to either the biomarker-guided approach or usual treatment. The goal is to see if personalized drug sequencing preserves kidney function over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin, Semaglutide, Finerenone
What this could lead to: If successful, this could show that matching drugs to individual biomarkers slows kidney function decline better than standard care, improving long-term outcomes for millions with chronic kidney disease.
What could go wrong: This is a phase 4 trial with 125 participants, so results may not apply to all patients. The benefit over standard care may be small, and side effects from combining these drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD)

Contacts and locations

Locations

Hospital Clinico de Valencia
NOT_YET_RECRUITING

Valencia, Spain
Lund University
NOT_YET_RECRUITING

Malmö, Sweden
Steno Diabetes Center Copenhagen
RECRUITING

Herlev, Denmark
University Medical Center Hamburg-Eppendorf
NOT_YET_RECRUITING

Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.